11 Best Short-Term Stocks to Invest in

Page 9 of 10

2. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Performance 1 Year: -42.86%

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) earns a spot on our list of 11 best short-term stocks to invest in. Amid revenue surges from the existing drugs, Revuforj and Niktimvo in Q2, FDA grants Priority Review for Revuforj’s sNDA.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage oncology company developing innovative cancer therapies through novel combinations and targeted agents in hematological and solid tumors. Operating from its headquarters in Massachusetts, the company has two FDA-approved products, Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab), a monoclonal antibody that blocks the CSF-1 receptor.

The company reported its Q2 financial results on August 4, 2025, where it highlighted $28.6 million in Revuforj net revenue, a 43% growth compared to the first quarter of 2025. Additionally, Niktimvo, in its first full quarter of launch, generated $36.2 million in net revenue, with Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)’s collaboration revenue from it amounting to $9.4 million, and the product already proving profitable for the company.

Additionally, the FDA has granted a Priority Review for Revuforj’s supplemental New Drug Application (sNDA) in relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia, with a PDUFA action date of October 25, 2025. The Priority Review potentially increases the likelihood of approval and improves the company’s outlook among investors.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)’s stock soared 21.45% this week, offering a notable short-term upswing despite a 42.86% annual decline.

Page 9 of 10